Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering
January 02, 2024 17:58 ET
|
Bluejay Diagnostics
ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony...
Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering
December 28, 2023 08:00 ET
|
Bluejay Diagnostics
ACTON, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony...
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)
December 27, 2023 09:00 ET
|
Bluejay Diagnostics
This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives. ACTON, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) --...
Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results
November 09, 2023 16:05 ET
|
Bluejay Diagnostics
ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient...
Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance
March 28, 2022 07:00 ET
|
Bluejay Diagnostics
ACTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing...
Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer
March 24, 2022 07:00 ET
|
Bluejay Diagnostics
ACTON, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a late-stage, pre-revenue diagnostics company focused on developing...
Bluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 10, 2022 07:00 ET
|
Bluejay Diagnostics
Testing program underway for lead product candidate, the Symphony IL-6 Test, in support of an FDA Marketing Application, planned for Q3 2022 2021 ended with approximately $19 million in cash expected...
Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA
January 31, 2022 07:00 ET
|
BlueJay Diagnostics
ACTON, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing...
Bluejay Diagnostics, Inc. Announces Pricing of Upsized $21.6 Million Initial Public Offering
November 10, 2021 08:15 ET
|
BlueJay Diagnostics
ACTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing...